NewsBenzingaAnixa Biosciences Announces Second Patient Has Been Treated In Fifth Cohort Of Its Ongoing Phase 1, Dose-Escalating, Clinical Trial Evaluating FSHR-Targeted CAR-T Therapy For Recurrent Ovarian Cancer Anixa Biosciences Announces Second Patient Has Been Treated In Fifth Cohort Of Its Ongoing Phase 1, Dose-Escalating, Clinical Trial Evaluating FSHR-Targeted CAR-T Therapy For Recurrent Ovarian Cancer Benzinga 2026.10.01 12:40 (GMT+0) Open on Benzinga Other news Gain Therapeutics Announces Poster Presentation At International Congress Of Parkinson’s Disease And Movement Disorders, October 4-8; MDS-UPDRS Motor Scores Demonstrated Stability To Baseline Recorded At Study Entry With No Disease Progression Among The... TD Cowen Reiterates Buy on Micron Technology, Maintains $1600 Price Target BOS Better Online Solutions Awarded $380K Order From Undisclosed Israeli Defense Client TD Cowen Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $55 Nvidia's Jensen Huang, Other CEOs Privately Confront Anthropic's Dario Amodei Over AI Doomsday Warnings Amid Trump's Tech Summit: Report Piper Sandler Maintains Neutral on Zions Bancorp, Lowers Price Target to $68
Gain Therapeutics Announces Poster Presentation At International Congress Of Parkinson’s Disease And Movement Disorders, October 4-8; MDS-UPDRS Motor Scores Demonstrated Stability To Baseline Recorded At Study Entry With No Disease Progression Among The...
TD Cowen Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $55
Nvidia's Jensen Huang, Other CEOs Privately Confront Anthropic's Dario Amodei Over AI Doomsday Warnings Amid Trump's Tech Summit: Report
